Core Viewpoint - Ordos City is focusing on developing the biopharmaceutical industry as a key industrial chain, aiming to create an ideal environment for industry transfer and growth [1][2]. Group 1: Business Environment - Ordos has been ranked first in Inner Mongolia's business environment assessment for five consecutive years, promoting a "warm city" business environment brand [1]. - The city has implemented the "Release, Management, and Service" reform and optimized the business environment 6.0 version, enhancing project approval processes and reducing costs for enterprises [1]. Group 2: Policy Support - Ordos has introduced unprecedented policies in technology and talent, including a new version of the technology and talent policy, to attract innovation and development [1][2]. - The city collaborates with top universities and research institutions to establish high-level scientific innovation platforms, fostering a strong talent pool [1]. Group 3: Financial Empowerment - Ordos has developed venture capital, equity investment, and patient capital, with state-owned enterprises participating in the establishment of 13 funds totaling 30.8 billion yuan to support industrial projects [2]. Group 4: Industry Advantages - The city possesses unique advantages in the biopharmaceutical sector, particularly in chemical raw materials, traditional Chinese medicine, and biopharmaceuticals, with a rich variety of high-quality medicinal materials [2]. - Ordos has over 60,000 acres of traditional Chinese medicine cultivation bases, producing 73,000 tons of high-quality medicinal materials annually, providing abundant natural resources for the biopharmaceutical industry [2]. Group 5: Research and Development - The city is actively promoting the innovation and development of traditional Chinese medicine through policies and collaborations with top research institutions [2]. - Ordos is engaging with leading research institutions and enterprises to advance cutting-edge biotechnologies, including synthetic biology and gene editing, accelerating clinical research applications of new technologies [2].